Dr. Joe Yeong possesses more than 10 years of translational research experience. He is the pioneer and key opinion leader in automation of quantitative multiplex (fluorescence-) immunohistochemistry (m-IHC/IF), utilising clinical autostainers to study and quantitate tumour immune microenvironment. He has established an integrative m-IHC/IF pathology platform in the Department of Anatomical Pathology, SGH which is the first of its kind in Asia-Pacific (APAC) region; providing a one-stop solution for scientists, clinicians, immunologists and pathologists to synergise their expertise in biomarker discovery and translation for clinical practice.


Principal Associate, Cancer Science Institute
Group Leader, Institute of Molecular and Cell Biology, A*STAR
Research Pathologist, Singapore General Hospital, Dept. of Anatomical Pathology
Visiting Associate Professor, Dept. of Surgery, Faculty of Medicine, University of Malaya
Visiting Fellow,Western Sydney University, Dept. of Pathology, Liverpool Hospital

Year(s) Degree (if applicable) Institute
2016 Associateship Royal College of Pathologist (British)
2014 PhD (Cancer Immunology, Integrative
Science & Engineering)
National University of Singapore
2009 Bachelor of Medicine, Bachelor of Surgery Fudan University
2019 to present Visiting Fellow (Western Sydney University, Dept. of Pathology, Liverpool Hospital)
2019 to present Principal Associate (Cancer Science Institute of Singapore, NUS)
2019 to present Visiting Associate Professor (Dept. of Surgery, Faculty of Medicine, University of Malaya)
2018 to present Group Leader (Institute of Molecular Cell Biology, A*STAR)
2017 to present Research Fellow (Dept. Anatomical Pathology, SGH)
2015 to 2017 Visiting Scientist (Dept. Anatomical Pathology, SGH)
2014 to 2018 Senior Research Fellow (Singapore Immunology Network)
2010 to 2014 PhD student (National University of Singapore)
A*STAR scholar (Singapore Immunology Network)
2009 to 2010 Medical Officer (Shanghai Zhongshan Hospital)


1. Tumour immunology – focusing on roles of tumour infiltrating leukocytes (TILs).
2. Tumour pathology – focusing on new biomarkers and technologies to improve current clinical diagnosis, and predict prognosis and treatment responsiveness of cancer.
3. Integrative translational research to combine tumour immunology and pathology (Immunopathology or Immuno-mapping) – focusing on application of immune markers in routine clinical practice for diagnosis and prognosis, with emphasis on cancer immunotherapy and precision medicine.
4. Others: Theranostics for immune-related disease such as liver fibrosis and infectious disease; natural compounds and its application in diseases and immune responses.

His works on breast cancer, liver cancer and colorectal cancer are included in multiple National Medical Research Council (NMRC) funded studies as well as pharmaceutical industry sponsored projects. He is a member of the British RCPath (associateship), United States and Canadian Academy of Pathology (USCAP) and Society for Immunotherapy of Cancer (SITC). His key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and further beyond. He is one of the winners of the Best Mentor award of NUS Wong Hock Boon Research Society in 2017 for his dedication to mentor medical students on translational research. He also served as a committee member in the World Immunotherapy Council (WIC) and is one of the organizers for its 2019 WIC Young Investigator Symposium in National Harbour, USA.

In 2018, he has set up an automated quantitative m-IHC/IF Immuno-Mapping service platform in IMCB, A*STAR as an official service portal to provide solutions for academic collaborators and industry partners who are keen to understand immunology profile and landscape of cancers and other diseases. This service platform is across partnership with SGH, National University of Singapore (NUS), Nanyang Technological University (NTU) and National Cancer Centre (NCC) with multi-disciplinary expertise contributions to provide the best solution. Powered by the state-of-the-art autostainer, 9+ colour imaging system and analytic packages, this platform is envisioned and well-prepared to become the APAC hub for Immuno-Mapping domain. The experience, track records, know-how as well as proprietary protocols and solutions that his group has built in the past few years safeguard the standard, quality and robustness of the platform. Other immuno-profiling methods, such as multi-colour high-dimensional flow cytometry (up to 24 markers), mass cytometry, multianalyte profiling and multi-photon imaging, that are available in the ecosystem complement the Immuno-Mapping platform and allow multi-modal integration and interpretation of data which would be essential in this era of immunotherapy.

Selected Publications

1. Yeong J, Lim JCT, Lee B, Li H, Ong CCH, et al. Prognostic value of CD8+PD-1+ immune infiltrates and PDCD1 gene expression in triple negative breast cancer. J Immunother Cancer. 2019 Feb 6;7(1):34.

2. Wee Felicia, Alkaff S, Lim JCT, Josh Loh, et al…Yeong J. An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr Virus-related tumours. Ann Diagn Pathol. 2018 Dec;37:12-19.

3. Lim CJ, Lee YH, Pan L, Lai L, Chua C, Wasser M, Tony Lim, Yeong J, et al. Multidimensional analyses reveal distinct immune microenvironment in hepatitis B virus-related hepatocellular carcinoma. Gut. 2018 Jul 3. pii: gutjnl-2018-316510.

4. Yeong J, Lim JCT, Lee B, Li H, Chia N, Ong CCH, et al. High Densities of Tumor-Associated Plasma Cells Predict Improved Prognosis in Triple Negative Breast Cancer. Front Immunol. 2018 May 30;9:1209.

5. Simoni Y, Becht E, Fehlings M, Loh C, Koo S, Teng K, Yeong J, et al. Bystander CD8+ T cells are abundant in human tumour infiltrates and lack expression of CD39. Nature. 2018 May;557(7706):575-579.

6. Yeong J, Jeffrey Lim, Chunjye Lim, et al. An automated staining protocol for seven-colour immunofluorescence of human tissue sections for diagnostic and prognostic use. Pathology. 2018 Apr;50(3):333-341.

7. Yeong J, L Gole, et al. Quantitative Imaging and Deep Profiling of Collagen Structure of Asian Triple Negative Breast Cancer: Novel Perspective for Breast Cancer MicroEnvironment, Mod Path. 2018 Mar; 31 (suppl 2).

8. Nei W-L, Jain A, Wang F-Q, Khor LK, Yeong JP-S, Han S-T, et al. Somatostatin receptor imaging in nasopharyngeal cancer. Annals of Nasopharynx Cancer 2018;2(2).

9. Yeong J, Thike AA, Ikeda M, et al. Caveolin-1 expression as a prognostic marker in triple negative breast cancers of Asian women. J Clin Pathol. 2018 Feb;71(2):161-167.

10. Yeong J, Thike AA, Young Ng CC, et al. A genetic mutation panel for differentiating malignant phyllodes tumour from metaplastic breast carcinoma. Pathology. 2017 Dec;49(7):786-789.